Workflow
Ionis (IONS) Q1 Loss Narrower Than Expected, Sales Miss
IONSIonis Pharmaceuticals(IONS) Zacks Investment Research·2024-05-08 15:42

Ionis Pharmaceuticals (IONS) reported a loss of 98 cents per share for first-quarter 2024, which was narrower than the Zacks Consensus Estimate of a loss of 1.10pershare.Thebottomlineincludescompensationexpensesrelatedtoequityawards.Excludingthesespecialitems,adjustedlosspersharewas77centsagainstalossof68centspershareintheyear−agoquarter.Totalrevenueswere1.10 per share.The bottom line includes compensation expenses related to equity awards. Excluding these special items, adjusted loss per share was 77 cents against a loss of 68 cents per share in the year-ago quarter.Total revenues were 119 million in the first quarter, missing the Zacks Consensus Estimate of $131.5 million. Revenues declined 1.2% yea ...